Semaglutide, Tirzepatide and Retatrutide: Receptor Targets and Trial History

Semaglutide, tirzepatide and retatrutide are three synthetic incretin-receptor agonist peptides that differ principally in how many gut-hormone receptors each one activates: semaglutide is a mono-agonist at the glucagon-like peptide-1 (GLP-1) receptor, tirzepatide is a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, and retatrutide is a triple agonist at the GIP, GLP-1 and glucagon (GCGR) receptors.

This page sets the three molecules side by side on receptor pharmacology, molecular design and published study history. It does not rank them, does not recommend one over another, and does not describe administration to humans or animals. All three are supplied for laboratory research only.

Regulatory status

Semaglutide and tirzepatide are active pharmaceutical ingredients in finished drug products that hold FDA marketing approval under specific brand names, manufactured under pharmaceutical quality systems and dispensed by prescription. Material supplied as a research chemical is not one of those approved drug products. It is not an approved drug, has not been reviewed by any regulatory authority for any purpose, and is not for human or animal consumption. Retatrutide holds no marketing authorization in any jurisdiction; as of 2026 it remains an investigational compound whose late-stage evaluation is conducted by its sponsor. The full terms under which this material is supplied are set out in the research use policy.

Comparative specifications

Receptor targets and signaling

The GLP-1 receptor, the GIP receptor and the glucagon receptor are all class B1 G protein-coupled receptors that signal predominantly through G_s and cyclic AMP. Because they share a receptor family, a single peptide backbone can be engineered to engage more than one of them, and the three compounds below represent successive steps along that design path.

Molecular design and half-life extension

All three peptides use the same general strategy for extending circulating half-life: substitution of protease-labile residues, plus conjugation of a fatty diacid that binds reversibly to serum albumin.

• Semaglutide. Lau et al. (2015) described the design programme that selected it, reporting two substitutions relative to human GLP-1 — 2-aminoisobutyric acid at position 8 and arginine at position 34 — with a fatty diacid attached through a spacer at lysine 26. The paper frames albumin affinity and dipeptidyl peptidase-4 resistance as the two variables being optimized.
• Tirzepatide. Coskun et al. (2018) described a fatty-acid-modified peptide built on the GIP sequence, incorporating 2-aminoisobutyric acid substitutions to resist enzymatic cleavage, and reported dual receptor activation in vitro.
• Retatrutide. Coskun et al. (2022) described a single-molecule triple agonist derived from the GIP sequence and similarly fatty-acid modified, and reported in vitro potency at all three receptors.

Research history and study models

Preclinical record

In murine work, Coskun et al. (2018) reported that tirzepatide acted at both the GIP and GLP-1 receptors to influence glucose tolerance in mice, using receptor-knockout comparisons to attribute the effects. Coskun et al. (2022) reported that in obese mice the glucagon-receptor component of retatrutide contributed through increased energy expenditure, a mechanism distinct from the reduction in caloric intake attributed to the GIP and GLP-1 receptor components. Both findings are murine and in vitro; neither was established in humans in those papers.

Clinical literature

Semaglutide has the longest published human record of the three. Marso et al. (2016) reported a randomized cardiovascular outcomes trial in adults with type 2 diabetes, and Wilding et al. (2021) reported a 68-week randomized placebo-controlled trial in adults with overweight or obesity. Tirzepatide has been examined in a comparable programme, including a 40-week randomized active-comparator trial reported by Frías et al. (2021), in which semaglutide served as the comparator, and a 72-week randomized placebo-controlled trial reported by Jastreboff et al. (2022). Retatrutide's peer-reviewed human record is the shortest of the three; the principal published trial is the 48-week randomized phase 2 trial in 338 adults reported by Jastreboff et al. (2023), and its later-phase evaluation was ongoing under the sponsor at the time of writing. This page does not restate trial results or compare them.

What the published record does not establish

The trial literature above concerns pharmaceutical-grade drug product administered under clinical supervision. It says nothing about research-grade material of unverified identity or purity, and it establishes no safety or performance profile for such material. Comparative evidence across the three compounds is thin: this page cites one trial in which two of them were studied against each other, and none in which retatrutide was compared with either of the others. Long-term comparative data across all three is not established by the sources cited here.

Identity, purity and documentation

Peptides of this size are typically characterized by reversed-phase HPLC for purity and by mass spectrometry for identity, with water content, counter-ion content and endotoxin reported separately. Because the three molecules differ in mass by several hundred daltons, mass spectrometry distinguishes them unambiguously; an HPLC purity figure alone does not. Analytical documentation for material supplied here is described under lab testing.

Handling and storage

Lyophilized peptide is generally held at −20 °C, desiccated and shielded from light, with repeated freeze–thaw cycles minimized. Guidance on laboratory reconstitution technique is collected in how to reconstitute peptides, and temperature and container considerations in peptide storage. Investigators preparing stock solutions of a defined molar concentration may find the peptide calculator useful, noting that the three compounds have different molecular weights.

Frequently asked questions

Is research-grade semaglutide the same thing as the approved drug product?

No. An approved drug product is a specific finished formulation manufactured, tested and released under a pharmaceutical quality system and authorized by a regulatory agency. Research-grade material is an unapproved chemical supplied for laboratory work, outside that framework.

What is retatrutide's regulatory status?

Retatrutide is not approved by the FDA or any other regulatory authority. Its published human data is early-phase, and its later-stage evaluation is conducted by its sponsor under investigational protocols.

How should lyophilized material be stored?

Sealed, desiccated, at −20 °C and protected from light. Shipment at ambient temperature for short periods is common for lyophilized peptides, but material should be returned to freezer storage on receipt.

What documentation should accompany material of this class?

A certificate of analysis identifying the lot, the analytical methods used, an HPLC purity result and a mass-spectrometric identity confirmation. Reports that state a purity percentage without naming the method or showing the chromatogram cannot be independently evaluated.

References

• Lau et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry.
• Marso et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine.
• Coskun et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism.
• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine.
• Frías et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.
• Coskun et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism.
• Jastreboff et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. The New England Journal of Medicine.